<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02125721</url>
  </required_header>
  <id_info>
    <org_study_id>16-00108</org_study_id>
    <secondary_id>1U54DK083908</secondary_id>
    <nct_id>NCT02125721</nct_id>
  </id_info>
  <brief_title>Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria</brief_title>
  <official_title>Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of escalating doses of cystine biding&#xD;
      thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which&#xD;
      is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall&#xD;
      goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by&#xD;
      larger doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystinuria is a rare genetic cause of kidney stones that leads to significant morbidity due&#xD;
      to the recurrent nature of the disease. As a result, a significant part of treatment is&#xD;
      focused on prevention of stone formation. Current methods of prevention include increasing&#xD;
      fluid intake, dietary modifications, alkali therapy, and cystine binding thiol drugs (CBTDs),&#xD;
      which help increase the solubility of cystine in the urine. At present, the dosing of CBTDs&#xD;
      is empiric, and not titrated to a specific measured effect. Our primary objective will be to&#xD;
      measure the effect of increasing doses of CBTDs on cystine capacity. The investigators&#xD;
      predict that higher dosages of these medications will lead to a more positive urinary cystine&#xD;
      capacity, or the ability of urine to take up more cystine (and therefore decreased risk of&#xD;
      stone formation). However, the dose at which increasing dosages of the medications cease to&#xD;
      provide additional benefit is unknown. The investigators will directly measure the cystine&#xD;
      capacity in the urine in response to increasing doses of medications to determine if there is&#xD;
      a dose at which the maximum benefit of the drug exists.&#xD;
&#xD;
      This is a cross-over trial of escalating doses. There will be four parts to the study. In the&#xD;
      first part, subjects will stop taking CBTDs for 7 days, and perform a 24-hour urine&#xD;
      collection on day 7. In part 2, they will take their usual CBTD (either tiopronin or&#xD;
      d-penicillamine) 1 gram per day for 7 days. They will perform another 24-hour urine&#xD;
      collection on day 7 of this study period. In part 3, they will take their usual CBTD at 2&#xD;
      grams per day for 7 days and in part 4 they will take their CBTD at 3 grams per day for 7&#xD;
      days. Again, they will perform 24-hour urine collections on day 7 of each period. The order&#xD;
      in which the parts of the study are performed will be randomized for each subject. The mean&#xD;
      cystine capacities in each part of the study will be compared to determine the effect of drug&#xD;
      dosage on urinary cystine capacity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cystine Capacity</measure>
    <time_frame>4 weeks on assigned therapy</time_frame>
    <description>We will test for a negative correlation between progressive increases in doses of thiol drugs and cystine capacity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cystinuria</condition>
  <arm_group>
    <arm_group_label>CBTD Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiopronin 1g per day</intervention_name>
    <description>500mg PO BID x 7 days</description>
    <arm_group_label>CBTD Patients</arm_group_label>
    <other_name>Thiola or tiopronin; d-penicillamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiopronin 2g per day</intervention_name>
    <description>1g PO BID x 7 days</description>
    <arm_group_label>CBTD Patients</arm_group_label>
    <other_name>Thiola or tiopronin; d-penicillamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiopronin 3g per day</intervention_name>
    <description>1.5g PO BID x 7 days</description>
    <arm_group_label>CBTD Patients</arm_group_label>
    <other_name>Thiola or tiopronin; d-penicillamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be a patient with a confirmed diagnosis of cystinuria.&#xD;
&#xD;
          -  Be already taking a CBTD (either D-penicillamine (Cuprimine速) or tiopronin (Thiola速)&#xD;
             as part of your medication regimen.&#xD;
&#xD;
          -  Be between 18 and 80 years of age&#xD;
&#xD;
          -  Be enrolled in the Cystinuria Registry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  You are not a patient with cystinuria&#xD;
&#xD;
          -  You are not already taking a cystine binding thiol drug&#xD;
&#xD;
          -  You have renal colic (if you are passing a stone)&#xD;
&#xD;
          -  You are scheduled to undergo a urologic procedure&#xD;
&#xD;
          -  You are unwilling or unable to provide informed consent in order to be able to&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Goldfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystinuria</keyword>
  <keyword>D-penicillamine (Cuprimine速)</keyword>
  <keyword>tiopronin (Thiola速)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02125721/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participant flow data was not provided &quot;per sequence&quot;. Multiple efforts were made to obtain information, but have not been successful.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CBTD Patients</title>
          <description>Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CBTD Patients</title>
          <description>Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cystine Capacity</title>
        <description>We will test for a negative correlation between progressive increases in doses of thiol drugs and cystine capacity</description>
        <time_frame>4 weeks on assigned therapy</time_frame>
        <population>Multiple efforts to contact the PI/study team for the relevant data have failed. Therefore, per intervention data are not available to be reported for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Increasing Doses of CBTD</title>
            <description>Intervention: CBTD 0-3 gm&#xD;
CBTD 0-3 gm: Oral CBTD 0-3 gm dose/day for 7 days, dose escalation</description>
          </group>
        </group_list>
        <measure>
          <title>Cystine Capacity</title>
          <description>We will test for a negative correlation between progressive increases in doses of thiol drugs and cystine capacity</description>
          <population>Multiple efforts to contact the PI/study team for the relevant data have failed. Therefore, per intervention data are not available to be reported for this assessment.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="131.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Days</time_frame>
      <desc>Multiple efforts to contact the PI/study team for the relevant data have failed. Therefore, per intervention data are not available to be reported for this assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>CBTD Patients</title>
          <description>Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Goldfarb</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212 263 0744</phone>
      <email>David.Goldfarb@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

